Prevalence and correlation of infusion-related reactions with haematological and demographic factors following the first dose of Rituximab infusion

After obtaining IEC clearance., we will register under CTRI, once we receive the approval from CTRI the study will be started by including all adult patients (≥18 years) treated in KMC Manipal with the first dose of Rituximab for any indication will be enrolled. Patient’s demographic factors like age, sex, performance status, comorbidity status, body surface -area, and body mass index; hematological parameters like- white blood cell count, absolute lymphocyte count, absolute neutrophil count, LDH, and hemoglobin; tumor-related factors like -type, grade, stage of lymphoma, B-symptoms, IPI, bulky disease  (> 10 cm ), bone marrow involvement, number of Extranodal sites, and LDH levels. Treatment-related factors like the type of chemotherapy, type of infusion-related reaction, defined as any adverse event occurring during or within 24 hours of rituximab infusion, time of onset of reaction, type of intervention, CTCAE grading, and consequences post-intervention, will be recorded.